Daniel Jorgensen joins PolyMedix
This article was originally published in Scrip
PolyMedix, a biotech developing novel drugs for the treatment of acute cardiovascular disorders and serious infectious diseases, has appointed Dr Daniel Jorgensen senior vice-president of clinical development and chief medical officer. Dr Jorgensen previously held senior leadership roles in the global research and development division of Pfizer, leading the company's first vaccine development group.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.